Form 8-K ASTRO MED INC /NEW/ For: May 17
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 17, 2016
ASTRO-MED, INC.
(Exact name of registrant as specified in its charter)
| Rhode Island | 0-13200 | 05-0318215 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
600 East Greenwich Avenue
West Warwick, RI 02893
(Address of principal executive offices) (Zip Code)
(401)-828-4000
Registrant’s telephone number, including area code
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| ITEM 2.02 | RESULTS OF OPERATIONS AND FINANCIAL CONDITION. |
On May 17, 2016, we issued a press release reporting our financial results for our fiscal first quarter ended April 30, 2016. A copy of the press release relating to such announcement, dated May 17, 2016 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information contained in Item 2.02 of this report and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS. |
| (d) | Exhibits |
| Exhibit |
Exhibit | |
| 99.1 | Press Release Dated May 17, 2016 | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ASTRO-MED, INC. | ||||||
| Dated: May 17, 2016 | By: | /s/ Joseph P. O’Connell | ||||
| Joseph P. O’Connell | ||||||
| Senior Vice President, Treasurer and Chief Financial Officer | ||||||
3
INDEX TO EXHIBITS
| Exhibit |
Exhibit | |
| 99.1 | Press Release Dated May 17, 2016 | |
4
Exhibit 99.1
|
News Release |
Contact:
Joseph P. O’Connell
Senior Vice President, Chief Financial Officer
(800) 343-4039
AstroNova Reports First-Quarter Fiscal 2017 Net Sales of
$24.1 Million; Diluted EPS of $0.14
Board of Directors Declares Regular Cash Dividend of $0.07 per share
Quarterly Highlights:
| • | Net sales increase 8.6 percent year-over-year, driven by growth in both the Product Identification (previously QuickLabel) and Test & Measurement segments |
| • | Both segments release significant new products |
| • | International sales up 13 percent on strong performance in Europe and Asia |
WEST WARWICK, R.I., May 17, 2016 – Astro-Med, Inc., d/b/a AstroNova (NASDAQ: ALOT), a leading manufacturer of data visualization technology products for the aerospace, specialty printing and test and measurement markets, today reported financial results for the first quarter of fiscal 2017 ended April 30, 2016.
“Our first-quarter performance highlights the progress of AstroNova’s ongoing strategic evolution as a global leader in products and technologies that acquire complex signal and network data and then transform it into human-usable formats for visualization and analysis,” said Gregory A. Woods, the Company’s President and Chief Executive Officer. “Our continuing focus on operational excellence, new product development and geographic expansion is helping to drive top-line growth, profitability and free cash flow, positioning us for a bright future.”
Net sales for the first quarter were $24.1 million, an increase of 8.6 percent from $22.2 million for the prior-year period. Sales in the Product Identification segment were up 6.1 percent to $16.6 million from $15.6 million in the first quarter of fiscal 2016. Sales in the Test & Measurement segment increased 14.4 percent to $7.5 million from $6.6 million in the comparable period of fiscal 2016. Domestic sales increased 6.7 percent and international sales were up 13.1 percent compared with the prior-year period.
|
Net income for the first quarter of fiscal 2017 was $1.0 million, or $0.14 per diluted share, compared with $1.2 million, or $0.16 per diluted share, for the same period a year earlier.
Operating expenses for the fiscal 2017 first quarter were $7.9 million, compared with $7.6 million for the year-earlier period.
Cash and marketable securities at April 30, 2016 totaled $23.3 million, compared with cash and marketable securities of $20.4 million at year-end fiscal 2016.
Recent Highlights
| • | AstroNova launched the QL-111 color label printer, a cost-efficient printer for industrial, commercial, warehouse and manufacturing and distribution facility applications. The QL-111 helps customers meet the demands of the Lean Manufacturing environment. |
| • | AstroNova received Honeywell Aerospace’s prestigious “Supplier of the Year” award for the Company’s outstanding achievement in design, development and delivery of flight deck printers. |
| • | AstroNova introduced the DDX100 SMARTCORDER™, the latest addition to the Company’s Daxus data acquisition platform. The DDX100 is a fully integrated portable system that combines the Daxus data acquisition engine and software with a large 14” color touchscreen interface. |
| • | AstroNova’s ToughWriter® 5 printer has been selected for inclusion in the Boeing catalog for the B737NG and B737 MAX aircraft, building on the Company’s strong relationship with Boeing. Airlines now have the option of including the ToughWriter 5 as a pre-installed component when ordering new 737 aircraft. |
Board Declares Quarterly Dividend
On May 16, 2016, the Board of Directors of Astro-Med, Inc. declared a regular quarterly cash dividend of $0.07 per share. The dividend, which represents a cash dividend of $0.28 per share on an annualized basis, is payable on June 28, 2016, to shareholders of record June 10, 2016.
| 2 | ||||
| ||||
Business Outlook
“We expect to achieve solid growth and profitability in fiscal 2017 while continuing the strategic, purposeful investments necessary to drive increasing returns for our shareholders,” Woods said.
Fiscal 2017 First-Quarter Conference Call
AstroNova will conduct an investor conference call at 9:00 a.m. ET today. Investors can participate in the conference call by dialing 888-516-2438 (U.S. and Canada) or 719-325-2219 (International) with passcode 301924.
Please join the call at least five minutes prior to the start time. You can also hear a live webcast of the call by accessing the Investors section of AstroNova’s website, www.astronovainc.com.
Following the live broadcast, an audio webcast replay of the call will be available at www.astronovainc.com. A telephone replay of the conference call will be available for seven days by dialing 888-203-1112 (U.S. and Canada) or 719-457-0820 (International) with passcode 9805438.
About AstroNova
Astro-Med, Inc., d/b/a AstroNova, a global leader in data visualization technologies, designs, manufactures, distributes and services a broad range of products that acquire, store, analyze and present data in multiple formats. The Product Identification segment offers a variety of hardware and software products and associated consumables that allow customers to mark, track and enhance the appearance of their products. Major brands include QuickLabel®, the industry leader in onsite digital color label printing. The Test and Measurement segment includes the T&M Product Group, which offers a suite of products and services that acquire and record electronic signal data from local and networked sensors. The Test and Measurement segment also includes a line of Aerospace Products that are used in aircraft flight decks to print flight plans, navigation information, ground communications and airport diagrams and in aircraft cabins to print maintenance data, receipts and passenger manifests. Astro-Med, Inc. is a member of the Russell Microcap® Index and the LD Micro Index (INDEXNYSEGIS: LDMICRO). Additional information is available by visiting www.astronovainc.com.
| 3 | ||||
|
| ||||
Forward-Looking Statements
Information included in this news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact, but rather reflect our current expectations concerning future events and results. These statements may include the use of the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “continues,” “may,” “will,” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning growth through acquisitions, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These risks, uncertainties, and factors include, but are not limited to, those factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2016 and subsequent filings Astro-Med makes with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The reader is cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this news release.
| 4 | ||||
|
| ||||
ASTRO-MED, INC.
Consolidated Statements of Income
In Thousands Except for Per Share Data
(Unaudited)
| April 30, 2016 |
May 2, 2015 |
|||||||
| Net Sales |
$ | 24,110 | $ | 22,206 | ||||
| Cost of Sales |
14,637 | 13,176 | ||||||
| Gross Profit |
9,473 | 9,030 | ||||||
| 39.3 | % | 40.7 | % | |||||
| Operating Expenses: |
||||||||
| Selling and Marketing |
4,831 | 4,329 | ||||||
| Research and Development |
1,444 | 1,796 | ||||||
| General and Administrative |
1,651 | 1,457 | ||||||
|
|
|
|
|
|||||
| 7,926 | 7,582 | |||||||
| Operating Income |
1,547 | 1,448 | ||||||
| 6.4 | % | 6.5 | % | |||||
| Other (Expense) Income, Net |
(52 | ) | 234 | |||||
|
|
|
|
|
|||||
| Income Before Taxes |
1,495 | 1,682 | ||||||
| Income Tax Provision |
476 | 471 | ||||||
|
|
|
|
|
|||||
| Net Income |
$ | 1,019 | $ | 1,211 | ||||
|
|
|
|
|
|||||
| Net Income per Common Share - Basic |
$ | 0.14 | $ | 0.17 | ||||
|
|
|
|
|
|||||
| Net Income per Common Share - Diluted |
$ | 0.14 | $ | 0.16 | ||||
|
|
|
|
|
|||||
| Weighted Average Number of Common Shares - Basic |
7,358 | 7,280 | ||||||
| Weighted Average Number of Common Shares - Diluted |
7,524 | 7,454 | ||||||
| Dividends Declared Per Common Share |
$ | 0.07 | $ | 0.07 | ||||
Selected Balance Sheet Data
In Thousands
(Unaudited)
| As of April 30, 2016 |
As of January 31, 2016 |
|||||||
| Cash & Marketable Securities |
$ | 23,308 | $ | 20,419 | ||||
| Current Assets |
$ | 57,672 | $ | 54,514 | ||||
| Total Assets |
$ | 80,737 | $ | 77,963 | ||||
| Current Liabilities |
$ | 11,175 | $ | 9,548 | ||||
| Shareholders’ Equity |
$ | 68,474 | $ | 67,373 | ||||
| 5 | ||||
|
| ||||